Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) insider Andreas P. Wagner sold 7,632 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $16.40, for a total transaction of $125,164.80. Following the sale, the insider now owns 223,474 shares of the company's stock, valued at approximately $3,664,973.60. This represents a 3.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Alignment Healthcare Stock Performance
Shares of NASDAQ:ALHC traded up $0.43 during midday trading on Friday, hitting $17.61. The company had a trading volume of 3,358,496 shares, compared to its average volume of 1,428,436. The company has a market cap of $3.38 billion, a price-to-earnings ratio of -22.87 and a beta of 1.49. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60. The company has a fifty day moving average of $14.90 and a two-hundred day moving average of $12.73. Alignment Healthcare, Inc. has a 12-month low of $4.46 and a 12-month high of $17.76.
Analyst Upgrades and Downgrades
ALHC has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Alignment Healthcare from $14.00 to $17.00 and gave the company a "neutral" rating in a research note on Thursday, March 6th. Stephens reiterated an "overweight" rating and set a $17.00 target price on shares of Alignment Healthcare in a research note on Monday, February 24th. William Blair reiterated an "outperform" rating on shares of Alignment Healthcare in a research note on Friday, February 28th. Stifel Nicolaus boosted their target price on shares of Alignment Healthcare from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Barclays boosted their target price on shares of Alignment Healthcare from $8.00 to $9.00 and gave the company an "underweight" rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $14.83.
View Our Latest Research Report on ALHC
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. R Squared Ltd bought a new position in Alignment Healthcare in the 4th quarter worth $55,000. RiverPark Advisors LLC bought a new position in Alignment Healthcare in the 4th quarter worth $106,000. Tower Research Capital LLC TRC boosted its holdings in Alignment Healthcare by 146.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company's stock worth $119,000 after buying an additional 6,286 shares during the period. Ballentine Partners LLC bought a new position in Alignment Healthcare in the 4th quarter worth $121,000. Finally, Aigen Investment Management LP bought a new position in Alignment Healthcare in the 4th quarter worth $129,000. Institutional investors own 86.19% of the company's stock.
About Alignment Healthcare
(
Get Free Report)
Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
Read More
Before you consider Alignment Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alignment Healthcare wasn't on the list.
While Alignment Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
